Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 282

1.

The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.

Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC.

Cancer Res. 2007 Feb 1;67(3):1090-8.

2.

TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.

Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC.

Carcinogenesis. 2008 Mar;29(3):528-35. doi: 10.1093/carcin/bgm289. Epub 2008 Jan 3.

PMID:
18174241
3.
5.

Loss of betaglycan expression in ovarian cancer: role in motility and invasion.

Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC.

Cancer Res. 2007 Jun 1;67(11):5231-8. Epub 2007 May 23.

7.
10.

Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.

Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP, Danielpour D, Wakefield LM.

Cancer Res. 1999 Oct 1;59(19):4834-42.

11.

A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.

Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M, Kadin ME, Lodish HF.

Mol Cell Biol. 1996 Jul;16(7):3480-9.

12.

Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.

Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK, Zborowska E, Brattain MG.

J Cell Physiol. 1998 Aug;176(2):424-34.

PMID:
9648930
13.

TGFBR3 loss and consequences in prostate cancer.

Sharifi N, Hurt EM, Kawasaki BT, Farrar WL.

Prostate. 2007 Feb 15;67(3):301-11.

PMID:
17192875
14.

Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.

Yang F, Strand DW, Rowley DR.

Oncogene. 2008 Jan 17;27(4):450-9. Epub 2007 Jul 16.

PMID:
17637743
15.

Inhibition of type III TGF-β receptor aggravates lung fibrotic process.

Ahn JY, Park S, Yun YS, Song JY.

Biomed Pharmacother. 2010 Sep;64(7):472-6. doi: 10.1016/j.biopha.2010.01.006. Epub 2010 Feb 24.

PMID:
20359848
16.

TGF beta (transforming growth factor beta) receptor type III directs clathrin-mediated endocytosis of TGF beta receptor types I and II.

McLean S, Di Guglielmo GM.

Biochem J. 2010 Jul 1;429(1):137-45. doi: 10.1042/BJ20091598.

PMID:
20406198
17.

Transforming growth factor-beta1 and prostate cancer.

Wikström P, Bergh A, Damber JE.

Scand J Urol Nephrol. 2000 Apr;34(2):85-94. Review.

PMID:
10903068
18.
19.

In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2.

del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY.

J Biol Chem. 2004 May 21;279(21):22765-72. Epub 2004 Mar 2.

20.

Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.

Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S, Yoshino G.

Horm Metab Res. 2006 Mar;38(3):159-66.

PMID:
16673206

Supplemental Content

Support Center